WO2024147073 - LIQUID ORAL FORMULATIONS OF NETUPITANT AND PALONOSETRON
National phase entry:
Publication Number
WO/2024/147073
Publication Date
11.07.2024
International Application No.
PCT/IB2023/063415
International Filing Date
31.12.2023
Title **
[English]
LIQUID ORAL FORMULATIONS OF NETUPITANT AND PALONOSETRON
[French]
FORMULATIONS ORALES LIQUIDES DE NÉTUPITANT ET DE PALONOSÉTRON
Applicants **
HELSINN HEALTHCARE SA
Via Pian Scairolo 9
6912 Lugano/Pazzallo, CH
Inventors
PARISI, Davide
Via Luciano Roncoroni 18
22100 Como, IT
FRIZZARIN, Stefano
Via Cesare Pavese 16
21010 Germignaga (Varese), IT
FABIANI, Flavio
Erlenmattstrasse 22
4058 Basel, CH
Priority Data
63/436,713
03.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1915 | |
| EPO | Filing, Examination | 13953 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 9510 |
Total: 26,542 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Orally administered liquid formulations of netupitant and palonosetron that are efficacious, chemically stable and physiologically balanced for safety and efficacy.[French]
Des formulations liquides administrées par voie orale de nétupitant et de palonosétron qui sont efficaces, chimiquement stables et physiologiquement équilibrées pour la sécurité et l'efficacité.